https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://glaucomaphysician.net/media/flcc2t52/1125-cover-final.jpg
Ophthalmology Management
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://glaucomaphysician.net/media/ef1permv/cover_nov25_web.jpg
Retinal Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://glaucomaphysician.net/media/kizp3ecu/1125-gp-cover-web.jpg
Glaucoma Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://glaucomaphysician.net/media/0jsmmz3o/op_1025_cover_final.jpg
Ophthalmic Professional
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://glaucomaphysician.net/media/jdnlmuh3/1025-oasc-cover-final.jpg
The Ophthalmic ASC
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://glaucomaphysician.net/media/aqbjxwjw/pp-cover.jpg
Presbyopia Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://glaucomaphysician.net/media/npjdtl1w/cp_november_cover.jpg
Corneal Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://glaucomaphysician.net/media/mvqdq2hc/nrp_cover_october_2024.jpg
New Retinal Physician
Monday, November 10, 2025
The company announced positive results from 2 clinical trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), for the treatment of elevated intraocular pressure in patients with mild-to-moderate open-angle glaucoma or ocular hypertension.
Friday, November 7, 2025
Data from the VITA Trial results show effectiveness and safety of the VisiPlate shunt at 1 year.
Sunday, October 19, 2025
New study shows machine learning algorithm significantly outperformed human graders at diagnosing glaucoma.
Friday, October 17, 2025
The latest updates include additional language support, new Ocular Motility and Cover Testing modules, and multiexam integration.
Friday, October 17, 2025
The company's digital SLT+YAG platform now features advanced HD imaging and seamless connectivity, among other features.
Thursday, October 16, 2025
The AI-powered device has tested 1 million eyes.
Thursday, October 16, 2025
Nordic Pharma, Inc. will feature Lacrifill Canalicular Gel, as well as recently published Lacrifill patient data and patient experience study results with attendees at AAO.
Wednesday, October 15, 2025
According to the company, AlloFlo Uveo is a first-of-its-kind surgical treatment targeting the uveoscleral pathway.
Tuesday, October 14, 2025
Interim 24-month data from the BIM-IOL system demonstrate sustained IOP and medication reductions, along with improved visual acuity in glaucoma patients.
Monday, October 13, 2025
The company formerly known as EyeQ Technologies will unveil new surgical and diagnostic tools at the AAO meeting this week in Orlando.
Monday, October 6, 2025
Integration and new variables aim to streamline clinical research and patient care.
Monday, October 6, 2025
The trial data shows sustained IOP lowering over 12 months. Nicox says it will submit a new drug application to the FDA in 2026.
Friday, September 26, 2025
Harrow Access for All program will provide a portal for streamlined prescribing, affordability, and home delivery.
Friday, September 26, 2025
The acquisition centers on MELT-300, a sublingual sedation candidate.
Thursday, September 25, 2025
The company's bimatoprost ophthalmic solution 0.01% will be available in 2.5 mL, 5 mL, and 7.5 mL container sizes.
Thursday, September 18, 2025
Results presented at ESCRS demonstrate clinically significant, long-term reductions in IOP and medication use for the Omni.
Monday, September 15, 2025
The IOP-lowering topical therapy represents the company’s first offering in ophthalmology.
Friday, September 12, 2025
The technology will be integrated into the Harmony connected care platform, enabling broader diagnostic reach.
Tuesday, September 9, 2025
The policy change, which begins October 1, means greater access to innovative glaucoma treatments.
Tuesday, August 26, 2025
Next-generation subconjunctival shunts expected to drive rapid expansion through 2030.
Tuesday, August 26, 2025
The phase 2 Nightingale trial will evaluate Qlaris Bio's QLS-111 in patients with normal-tension glaucoma.
Thursday, August 21, 2025
In the phase 3 study, NCX 470 met the primary endpoint of noninferiority to latanoprost in lowering IOP.
Thursday, August 21, 2025
The Series C funding will support the commercial launch of the company’s biointerventional glaucoma therapy this fall.
Thursday, August 21, 2025
A $5 million donation from the Barry Foundation will support the development of neuroprotective therapies.
Wednesday, August 13, 2025
The ADAPT study will evaluate the safety and effectiveness of the company’s Calibreye Titratable Glaucoma Therapy Surgical System.
By Rene Luthe
Friday, August 8, 2025
After promising results in Australia, the phase 2b trial will evaluate the safety and efficacy of PA5108 in 75 patients.
Tuesday, August 5, 2025
The acquisition includes the EVO family of lenses for vision correction for patients with moderate to high myopia, with or without astigmatism.
Monday, July 7, 2025
The company has added more than 100 products to its suture and needle portfolio.
Monday, July 7, 2025
5-year compound annual revenue growth rates are forecasted to grow in emerging markets.
Tuesday, June 24, 2025
The implant, which elutes an endothelin receptor antagonist, improved optic nerve structure and function independent of IOP lowering.
Tuesday, June 10, 2025
Qlaris Bio’s QLS-111-FDC would combine 2 mechanisms to improve glaucoma pressure control.
Friday, May 16, 2025
Exploratory results bolster understanding of NCX 470 without altering development path.
Wednesday, May 14, 2025
A new clear tip enhances surgical visibility.
Thursday, May 8, 2025
The company says the phase 1/2a trial data support the potential of PER-001 as the first disease-modifying treatment for glaucoma.
Monday, April 28, 2025
According to 18-month data presented at ASCRS, cataract patients who received the lenses showed clinically meaningful IOP reduction along with improved VA.
Tuesday, April 22, 2025
Surgeons attending the ASCRS meeting this week can preview the new MIGS system.
Thursday, April 17, 2025
The Laser Endoscopy Ophthalmic System is designed for early-stage glaucoma as well as a wide spectrum of glaucoma types.
Friday, March 21, 2025
The companies seek to combine their drug delivery technologies in a potential $92 million transaction.
Tuesday, March 18, 2025
The bioreinforced cyclodialysis procedure using the CycloPen system reduced IOP and medication use over 2 years.
Tuesday, March 11, 2025
The Inspire device integrates diagnostic technology with patient education and data analysis.
Friday, March 7, 2025
The enhanced dataset will help clinicians detect and manage eye diseases at an earlier stage.
Tuesday, March 4, 2025
The AI-powered Advanced Optic Disc Analysis module evaluates optic disc parameters using optical coherence tomography, providing personalized assessments by accounting for individual disc sizes and angle of rim absence.
Tuesday, March 4, 2025
The new ophthalmic microscope system brings Haag-Streit’s optics into the operating room, providing sharp clarity and precision during ophthalmic surgeries.
Friday, February 28, 2025
The goal of the annual observance is to provide employers and employees with important information to help keep eyes safe and healthy at work.
Friday, February 21, 2025
The Eye Health Summit, a new global patient-centered event dedicated to integrative eye health, will take place May 1-7 as a free hybrid event.
Wednesday, February 19, 2025
Alcon’s automated laser enables treatment without a gonio lens or manual aiming.
Tuesday, February 18, 2025
New World Medical's device can be used to deliver viscoelastic fluid and perform trabeculotomy.
Saturday, February 15, 2025
The next-generation system integrates ultrawidefield imaging with improved diagnostic support.
Friday, February 14, 2025
Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL) is a bioequivalent and therapeutically equivalent to the reference listed drug, Xalatan Ophthalmic Solution, 0.005% of Upjohn US 2 LLC, the company said in a press release.
Thursday, February 13, 2025
The VR-based system now includes visual acuity testing alongside other eye exams.
Wednesday, February 5, 2025
Qlaris Bio reports positive phase 2 results for its investigational drug treatment QLS-111 in glaucoma and OHT patients.
Wednesday, February 5, 2025
Adam Szaronos takes over top leadership role from company founder Dr. Sean Ianchulev, who will remain involved as board chair and CMO.
Monday, February 3, 2025
EyeXchange Solutions connects experienced and emerging surgeons across cataract, glaucoma, and retina specialties to share insights, refine techniques, and address complex cases.
Thursday, January 23, 2025
The American Medical Association comments on a recent statement by US insurer UnitedHealth that it will work toward easing prior authorization rules.
Wednesday, January 22, 2025
The event will highlight the growing role of artificial intelligence in glaucoma diagnosis and management.
Tuesday, January 14, 2025
Throughout January, Bausch + Lomb and Glaucoma Research Foundation will spotlight educational resources and share stories of individuals and families living with glaucoma to raise awareness of the disease.
Monday, January 13, 2025
With innovative therapies addressing glaucoma and geographic atrophy currently in development, the acquisition of Whitecap Bioscience's strengthens B + L’s expanding clinical-stage pipeline.
Tuesday, January 7, 2025
The deal allows each company to focus on strengths.
Monday, January 1, 0001
The Investigational Device Exemption allows the SAPPHIRE trial of VisiPlate to move forward.
